Table of Contents
Advances in Otolaryngology
Volume 2015 (2015), Article ID 245613, 4 pages
Research Article

Incidence of Cisplatin Induced Ototoxicity in Adults with Head and Neck Cancer

1Henry Ford Health System, Department of Otolaryngology-Head & Neck Surgery, 2799 West Grand Boulevard, Detroit, MI 48202, USA
2Henry Ford Health System, Department of Radiation Oncology, 2799 West Grand Boulevard, Detroit, MI 48202, USA

Received 26 August 2015; Accepted 2 November 2015

Academic Editor: Giuseppe Mercante

Copyright © 2015 Joshua B. Greene et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. To elucidate the incidence of cisplatin induced ototoxicity in adult patients, with a focus on an adult population. Study Design. IRB approved retrospective study. Methods. The charts of patients who underwent cisplatin therapy from 1995 to present were reviewed. Inclusion criteria were (1) cisplatin as the primary chemotherapeutic agent and (2) hearing evaluation performed prior to and after treatment. Audiometric thresholds were measured by presenting pure-tone stimuli at 0.25 to 10.0 kHz. Criteria for hearing loss were based on the Chang criteria. Cochlear radiation doses were also calculated in patients with primary tumors in their head and neck or brain. Results. There were 1565 patients that had undergone therapy with cisplatin from 1995 to 2014, which 30 met inclusion criteria. Eight were patients treated for head and neck or brain cancer. Evaluation with ANOVA testing identified statistically significant decline in audiometric scores for WRS and pure tone frequencies 500, 2000, 4000, 6000, and 8000 Hz in the right ear. Overall, hearing loss was noted with 63% incidence and in patients who received radiation to their cochlea and cisplatin. Conclusion. The incidence of cisplatin induced ototoxicity was significant and even more prevalent in those patients receiving both cisplatin and radiation to their cochlea.